EOG Resources Inc vs Eli Lilly And Co — how do they compare? EOG Resources Inc trades at $148.51 (market cap $75.64B), while Eli Lilly And Co trades at $1,167.38 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 14× EOG Resources Inc's market cap, and EOG Resources Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Eli Lilly And Co for 93 Days on average.
| EOG | LLY | |
|---|---|---|
Market Cap | $75.64B | $1.06T |
Volume | 2,041,336 | 2,297,239 |
Sector | Energy | Health |
52-Week High | $153.74 | $1.28K |
52-Week Low | $101.78 | $799.57 |
Typical Hold Time | 59 Days | 93 Days |
Enterprise Value | $78.99B | $1.11T |
Dividend Yield | 2.83% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $144.21, down 0.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $164.77 implying 14% upside. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations, while maintaining strong profitability with a 25.81% net income margin and 22.51% ROE. Recent news highlights operational strength and disciplined capital allocation, with upcoming Q3 2026 results scheduled for November 6, 2026.
EOG presents a compelling value opportunity with attractive valuation multiples (P/E of 11.22, EV/EBITDA of 5.68) and strong shareholder returns through dividends. Key risks include oil price volatility, as seen in recent sector pullbacks, and execution of growth targets amid macroeconomic uncertainty. The absence of sell ratings from analysts and institutional accumulation support a positive medium-term outlook, though investors should monitor energy market dynamics and quarterly results.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →